VistaJet Records 39% EBITDA Growth With Strong First Quarter 2017 Results
VistaJet continues to gain market share across all markets
For the 13 weeks to 31 March 2017:
Flight revenues increased by 22% globally year-over-year.
EBITDA grew 39% year-over-year due to increased yields and efficiency.
New Program hours sold up 79% Q1 2017 against Q1 2016.
Program Membership accounts for majority of total hours flown in Q1 2017 at 55%.
LONDON, June 01, 2017 (GLOBE NEWSWIRE) -- VistaJet, the first and only global aviation company, has today announced yet another record quarter, again demonstrating its ability to consistently capture greater market share with its strong value proposition of asset free risk and truly global access.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/9e3d1364-eb1f-4e73-aa64-4dbcecb3cf76
The company recorded EBITDA growth of 39% year-on-year following a record Q1 sales success, and increased yields and efficiency due to its global infrastructure and a continued focus on technology.
The company's decision to grow its fleet to a total of over 70 identically branded and globally positioned aircraft continues to support its growth, and the average utilization trend was positive month-on-month from January 2017 to March 2017.
In the traditionally weakest quarter of the year for the aviation industry, VistaJet recorded a 22% growth in flight revenues year-on-year. The majority of growth came from VistaJet's Program segment, with existing customers utilizing and upsizing their contracts and new clients choosing to subscribe to multi-year agreements. Sales of new annual Program hours increased by 79% year-on-year, demonstrating the company's position as the only alternative to full or fractional aircraft ownership in the private aviation market. Program customers flew more hours in the first quarter than in any other period in VistaJet's history, accounting for 55% of total hours globally, up from 53% against the same quarter last year.
VistaJet's On Demand segment also grew year-on-year, with revenues increasing by 14% in spite of Easter falling outside of Q1 this year. Total On Demand flight hours remained steady year-on-year whilst live hours increased by a staggering 4% as the improvement in the ferry factor drove a decline in empty flight hours. Empty legs have long been a challenge for private aviation businesses, as companies with less scale and operational efficiency have to relocate their aircraft to pick up passengers. The company recently announced a 'Ferry Free World' for its Program clients.
VistaJet continues to record growth across the globe. The company increased its market share not only in the U.S. and Asia, both key target growth markets, but also in the more mature markets of Europe, Russia and CIS. VistaJet saw an increase of 15% year-on-year in flight hours in Europe, highlighting that the company continues to see significant growth potential in its established markets.
The U.S. business remains a driving factor in VistaJet's flight hour growth and prospect pipeline. Flight hours in North America increased by 54% year-on-year. The company also increased its regional customer base and the number of aircraft positioned in the area, which helped it to deliver flight hours growth of 43% also in Central and South America.
VistaJet performed strongly in Asia, and Program customers within the region accounted for 25% of total hours sold during Q1 2017. As a result of their global flying and access needs, both corporate and private individual Program customers in Asia are mainly flying outside of the region to Europe, the Middle East and North America, helping to drive an increase in global flight hours.
VistaJet will continue to grow hours and revenues on its established and leading aircraft and technology infrastructure, improving utilization, margins and the company's financial strength. VistaJet, as the leading global private aviation company, is continuing to benefit from the trends away from asset ownership and secure new customers who previously had to choose between whole aircraft, fractional ownership, and an inconsistent and inferior charter offering.
VistaJet is the first and only global aviation company. On its fleet of silver and red business jets, VistaJet has flown corporations, governments and private clients to 187 countries worldwide. Founded in 2004 by Thomas Flohr, the company pioneered an innovative business model where customers pay only for the hours they fly, free of the responsibilities and asset risks linked to aircraft ownership. VistaJet's signature Program service offers customers a bespoke subscription of flight hours on its fleet of mid and long range jets, to fly them anywhere and at any time.
More VistaJet information and news at vistajet.com.
T: +44 203 617 3077
M: +44 7834 335505
+44 207 251 3851
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: VistaJet Ltd via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Luxembourg Announced as SNOMED International's Newest Member24.5.2018 15:16 | Pressmeddelande
London, United Kingdom, May 24, 2018 (GLOBE NEWSWIRE) -- SNOMED International and Agence eSanté Luxembourg are pleased to announce that Luxembourg has joined the organization as its thirty-second Member. Luxembourg, one of the leading nations in the area of information and communication technology, has set the development of eHealth technologies as a high priority. Agence eSanté, Luxembourg's national agency for the exchange and sharing of medical data, has set an overall mission to facilitate clinical information exchange both within Luxembourg and across other international actors. To work towards this reality, the agency has taken part in discussions about standardization across Europe, a contributing building block achieved with its membership in SNOMED International. With their membership, Agence eSanté has committed their support for the use of structured clinical terminology. When applied to the health sector, interoperability ensures that information systems, and through them h
SEMAFO Signs Underground Mining Services Contract with AUMS24.5.2018 14:00 | Pressmeddelande
MONTREAL, May 24, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX:SMF) (OMX:SMF) reports that it has signed a mining services contract with African Underground Mining Services ("AUMS") to provide turnkey mining services for Siou underground. AUMS is a well-known and reputable mining contractor with underground experience in Burkina Faso and across Africa. Under the mining services contract, AUMS will be responsible for supplying the mining fleet and a skilled labour force for Siou underground in addition to ensuring development, production and auxiliary services. SEMAFO will provide technical services including geology and engineering as well as leveraging the existing surface infrastructure at Mana. The mining services contract has a term of 70 months. The economic terms of the mining services contract are consistent with the economics presented in the Mana pre-feasibility study filed March 29, 2018 on SEDAR. Preparatory work has already commenced on Siou underground with full project deplo
Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors24.5.2018 13:00 | Pressmeddelande
- IND Accepted in April by the U.S. FDA for MCLA-158 - UTRECHT, The Netherlands, May 24, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the first patient has been dosed in a Phase 1, first-in human clinical trial of MCLA-158 in patients with solid tumors with an initial focus on metastatic colorectal cancer. The trial will be conducted in Europe, where several Clinical Trial Applications (CTAs) have been approved to date. The Company also announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for MCLA-158, which was accepted by the FDA in April 2018. With this acceptance, Merus plans to open additional sites for this trial in the United States. MCLA-158 is designed to bind to cancer stem cells expressing leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5) and epidermal grow
PRA Named International Clinical Research Company of the Year24.5.2018 10:00 | Pressmeddelande
RALEIGH, N.C., May 24, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) is pleased to announce it was recognized by PharmaTimes as the International Clinical Research Company of the Year. This is the fifth year in a row that PRA has received this award. "This award celebrates excellence in the clinical research industry and we are honored to once again be recognized by our peers," said Colin Shannon, President and Chief Executive Officer. "This award is possible thanks to the incredibly talented PRA team members we have working around the world who are deeply committed to their work in bringing new and life-saving therapies to the patients who need them." PRA also swept the Clinical Research Associate and Clinical Trial Administrator categories capturing a total of 11 awards. These awards follow PRA's recognition earlier this month in the PharmaTimes Americas competition where PRA also received 11 awards, including Company of the Year. The PharmaTimes, International Cli
Immunicum AB: Inbjudan till investerarträff24.5.2018 08:00 | Pressmeddelande
Pressmeddelande 24 maj 2018 Immunicum AB: Inbjudan till investerarträff Immunicum AB (publ; IMMU.ST) meddelade i dag att bolaget kommer att anordna en investerarträff i Kalmar den 13 juni kl. 18:00 CEST. Carlos de Sousa, Immunicums VD, kommer att hålla en presentation av det dagsaktuella läget, och han och övriga i ledningen kommer vara tillgängliga för att svara på frågor. Kalmar Datum: Onsdag 13 juni 2018 Tid: 18:00 - 20:00 CEST Plats: Kalmar Slott, Kungsgatan 1, 392 33 Kalmar För att delta på träffen, skicka ett mejl till firstname.lastname@example.org med ditt fullständiga namn. För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: email@example.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: firstname.lastname@example.org Media Relations Gretchen Schweitzer och Joanne Tudorica Trophic Communications Telefon: +49 172 861 8540 E-post: email@example.com Om Immunicum AB (publ) Immunicum etablerar ett unikt angreppssätt inom im
Immunicum AB: Invitation to Investor Event24.5.2018 08:00 | Pressmeddelande
Press Release 24 May 2018 Immunicum AB: Invitation to Investor Event Immunicum AB (publ; IMMU.ST) announced today that the Company will host an investor event in Kalmar on June 13 starting at 18:00 CEST. Carlos de Sousa, CEO of Immunicum, will give the current corporate presentation and he and other members of the Immunicum leadership team will be available for a question and answer session. Kalmar Date: Wednesday, June 13, 2018 Time: 18:00 - 20:00 CEST Location: Kalmar Slott, Kungsgatan 1, 392 33 Kalmar To register to attend the event, please send an email to firstname.lastname@example.org with your full name. For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: email@example.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: firstname.lastname@example.org Media Relations Gretchen Schweitzer and Joanne Tudorica Trophic Communications Telephone: +49 172 861 8540 E-mail: email@example.com About Immunicum AB (publ) Immunicum is establis
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum